Product Description: PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively[1].
Applications: Metabolism-protein/nucleotide metabolism
Formula: C144H225F3N40O41S
Citations: Nature. 2024 Mar;627(8002):149-156./Cell Metab. 2022 Nov 11;S1550-4131(22)00490-9.
References: [1]Gourlet P, et al. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur J Pharmacol. 1995 Dec 4;287(1):7-11./[2]Schäfer H, et al. Structural motifs of pituitary adenylate cyclase-activating polypeptide (PACAP) defining PAC1-receptor selectivity. Regul Pept. 1999 Feb 5;79(2-3):83-92./[3]Lindén A, et al. Inhibition of bronchoconstriction by pituitary adenylate cyclase activating polypeptide (PACAP 1-27) in guinea-pigs in vivo. Br J Pharmacol. 1995 Jul;115(6):913-6.
Molecular Weight: 3261.68
Compound Purity: 99.87
Research Area: Metabolic Disease; Neurological Disease
Solubility: DMSO : 250 mg/mL (ultrasonic)/H2O : 12.5 mg/mL (ultrasonic)
Target: PACAP Receptor
Deutsch
English
